Valentis VLTS Pages on BioPortfolio:

BioPortfolio - Valentis
Valentis - Entry on Bioportfolio's Biocorporate Database. ... Valentis (VLTS) Financial information Links from Barchart. VLTS Quote from from Barchart.com ...
http://www.bioportfolio.com/biocorporate/10726-Valentis.html...

NASDAQ Biotechnology Companies - sangamo - zymogenetics
ULAB · UNILAB CORP, Nasdaq, Services to Med Profs. USON · US ONCOLOGY INC, Nasdaq, Services to Med Profs. VLTS · VALENTIS CORP, Nasdaq, Biotech ...
http://www.bioportfolio.com/nasdaq/nasdaq_sangamo_zymogeneti...

Results from other life science and pharmaceutical sites:

BioSpace - Valentis, Inc. News, Search Jobs, Events
Valentis, Inc. (VLTS)'s Common Stock to be Quoted on the NASD's Over-The-Counter Bulletin Board 6/21/2007 11:44:37 AM More. ...
http://www.biospace.com/company_profile.aspx?CompanyId=51104...

Licensing Highlights Saloni Shah & Danny Chan
Valentis entered VLTS-589 into a peripheral arterial disease. (PAD) phase I/II clinical trial in June 2001; the phase II. portion of the trial was initiated
...
http://www.biomedcentral.com/content/pdf/cd-613745.pdf...

Centient Investor Release: Biggest Biotech Winners An - News ...
The biggest losers in Q3 were Maxim (MAXM) at 71% and Valentis (VLTS) at 62%. Exact (EXAS), Ciphergen (CIPH), and Immunomedics (IMMU) follow, ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1767982...

Valentis Announces Settlement of Patent Infringement Litigation
BURLINGAME, Calif., July 8 /PRNewswire-FirstCall/ -- Valentis, Inc. (Nasdaq: VLTS) announced that its wholly-owned subsidiary, PolyMASC Pharmaceuticals plc,
...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

BioSpace offers Pharmaceutical, Biotechnology and Healthcare ...
Valentis, Inc. (VLTS) To Web Cast The Mechanism Of Action For Its VLTS-934 Product 5/18/2005 More... Cook (Canada) Inc. To Begin First International Trial
...
http://www.biospace.com/news_by_disease_results.aspx?TheRxId...

Angiogenesis - SMi Conference Patrick Foley
Valentis intends to file. an IND early in 2005 to begin clinical trials in ischemic heart. disease as a second indication for VLTS-589, and believes ...
http://www.biomedcentral.com/content/pdf/cd-543752.pdf...

BioSpace - Urigen N.A. News, Search Jobs, Events
Valentis, Inc. (VLTS) Announces Effectiveness of Registration Statement for the Proposed Merger With Urigen N.A. 6/12/2007 2:24:36 PM More. ...
http://www.biospace.com/company_profile.aspx?CompanyId=10027...

Edward G. "Ted" Spack Joins SRI International
Prior to InterMune, Dr. Spack was director of product discovery and director of immunology for Valentis, Inc. [Nasdaq: VLTS], which designs DNA-based ...
http://www.sri.com/news/releases/12-01-03.html...

BioSpace - Urigen Inc. News, Search Jobs, Events
19 Oct 2005 ... The Day In Review: Urigen Inc. Uses Valentis, Inc. (VLTS) For Reverse Merger 10/ 6/2006 6:07:58 PM More... Valentis, Inc. (VLTS) And Urigen ...
http://www.biospace.com/company_profile.aspx?CompanyId=99552...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.